1.14
+0.02(+1.79%)
Currency In USD
| Previous Close | 1.12 |
| Open | 1.12 |
| Day High | 1.2 |
| Day Low | 1.11 |
| 52-Week High | 18.75 |
| 52-Week Low | 1.09 |
| Volume | 33,626 |
| Average Volume | 101,211 |
| Market Cap | 8.74M |
| PE | -0.06 |
| EPS | -17.76 |
| Moving Average 50 Days | 1.52 |
| Moving Average 200 Days | 3.21 |
| Change | 0.02 |
If you invested $1000 in Eterna Therapeutics Inc. (ERNA) 10 years ago, it would be worth $0.12 as of September 29, 2025 at a share price of $1.14. Whereas If you bought $1000 worth of Eterna Therapeutics Inc. (ERNA) shares 5 years ago, it would be worth $1.11 as of September 29, 2025 at a share price of $1.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
GlobeNewswire Inc.
Sep 17, 2025 12:30 PM GMT
Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trialsCAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -
Ernexa Therapeutics Provides Update on Operational Excellence and Performance
GlobeNewswire Inc.
Sep 10, 2025 12:30 PM GMT
The company’s operating loss declined by 51% year-over-year, reflecting a laser focus on relentless execution and significant progress in expense reductionCAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), deve
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 03, 2025 1:30 PM GMT
CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will be featured as a pre